KR0127777B1 - Anti gastritis and anti-ulcer drugs in upatiline - Google Patents
Anti gastritis and anti-ulcer drugs in upatilineInfo
- Publication number
- KR0127777B1 KR0127777B1 KR1019940000147A KR19940000147A KR0127777B1 KR 0127777 B1 KR0127777 B1 KR 0127777B1 KR 1019940000147 A KR1019940000147 A KR 1019940000147A KR 19940000147 A KR19940000147 A KR 19940000147A KR 0127777 B1 KR0127777 B1 KR 0127777B1
- Authority
- KR
- South Korea
- Prior art keywords
- gastritis
- ulcer
- upatiline
- present
- induced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000007882 Gastritis Diseases 0.000 title abstract description 19
- 239000003699 antiulcer agent Substances 0.000 title abstract description 4
- 241000638249 Artemisia mongolica Species 0.000 claims abstract description 4
- 235000003631 Artemisia mongolica Nutrition 0.000 claims abstract description 4
- 239000013078 crystal Substances 0.000 claims abstract description 4
- 238000002844 melting Methods 0.000 claims abstract description 4
- 230000008018 melting Effects 0.000 claims abstract description 4
- 208000025865 Ulcer Diseases 0.000 claims description 10
- 231100000397 ulcer Toxicity 0.000 claims description 10
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract 1
- MTVPOQKYYUETRT-UHFFFAOYSA-N Eupatilin Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 MTVPOQKYYUETRT-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- FHHSEFRSDKWJKJ-UHFFFAOYSA-N eupafolin Natural products C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=C(O)C(O)=C1 FHHSEFRSDKWJKJ-UHFFFAOYSA-N 0.000 description 8
- DRRWBCNQOKKKOL-UHFFFAOYSA-N eupatilin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(O)C=C2O1 DRRWBCNQOKKKOL-UHFFFAOYSA-N 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 5
- 229960001380 cimetidine Drugs 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 240000006891 Artemisia vulgaris Species 0.000 description 3
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 침쑥(Artemisia mongolica)의 지상부 전초에서 다음 구조식The present invention in the above-ground outpost of Artemisia mongolica
을 가지며 융점이 232-233℃이고 분자량이 344인 당황색 침상결정성의 유파티린의 추출방법 및 이물질을 항위염 및 항궤양제로서의 사용에 관한 것이다.The present invention relates to a method for the extraction of pale yellow acicular crystals of euclitin having a melting point of 232-233 ° C and a molecular weight of 344, and the use of foreign substances as anti- gastritis and anti-ulcer agents.
Description
본 발명은 항위염 및 항궤양제로서의 유파티린(Eupatilin)의 새로운 용도 및 그 추출법에 관한 것이다.The present invention relates to a novel use of Eupatilin as an anti-gastritis and anti-ulcer agent and its extraction method.
종래 위염 및 위궤양 치료제라고 하면 보통 시메티딘(Cimetidine)을 연상케하나 본 발명자등은 유파티린의 위염 및 궤양치료효과가 우수함을 발명하게 이르렀으며 이 유파티린을 참쑥(Artemisia mongolica)의 지상부 전초에서 추출 수득하였음도 본인들이 최초로 달성하게 된 것이다.Conventional agents for treating gastritis and gastric ulcers are usually associated with cimetidine, but the present inventors have come to invent an excellent effect of treating gastritis and ulcers of eupatilin, and extracting the eupatilin from the above-ground outposts of Artemisia mongolica It was the first thing they achieved.
본 발명자등은 전통적으로 위장질환에 쓰이는 생약재 15종을 선정하여 흰쥐를 실험적으로 위염을 유발시켜 이들 실험동물에서 위염에 대한 효과를 추구한 결과 참쑥의 잎인 애엽에서 추출된 물질이 위염 및 궤양치료에 우수한 효과를 나타냄을 확인하여, 그 유효성분을 분리추구하여 이루었다.The present inventors have selected 15 kinds of herbal medicines traditionally used for gastrointestinal diseases and induced gastritis in rats, and as a result of pursuing the effect on gastritis in these experimental animals, the material extracted from the leaf lobe of wormwood was used for the treatment of gastritis and ulcer. Confirmed to show an excellent effect, was achieved by separating the active ingredient.
유파티린은 참쑥의 지상부 전초에서 불리되는 융점 232-233C의 담황색 침상결정성 물질로서 다음과 같은 구조식으로 표시되는 물질이고,Eupatilin is a pale yellow needle-like crystalline material of melting point 232-233C, which is disadvantageous in the ground shoots of mugwort, and is represented by the following structural formula,
이는 종래의 위염 및 궤양치료제인 시메티딘(Cimetidine)에 비해 5배 정도의 치료효과를 나타내는 것이다.This is about 5 times the therapeutic effect compared to conventional gastritis and ulcer cimetidine (Cimetidine).
본 발명의 유파티린의 추출법 및 항위염 및 항궤양에 대한 효과를 이하 실시예에서 상세히 설명하겠다. 다만 본 발명은 이 실시예에 한정하는 것은 아니다.The extraction method of the upatin of the present invention and the effects on anti-gastritis and anti-ulcer will be described in detail in the following Examples. However, the present invention is not limited to this embodiment.
[실시예 1]Example 1
그림 1과 같이 참쑥(Artemisia mongolica) 2kg을 70%의 메탄올로 3회 추출한 메탄올 추출물(250g)을 핵산으로 탈지후 크로로포름(CHCl3)으로 분획하여 얻은 분획물(30g)을 실리카겔 칼럼(Silica gel Column)에 충진하여 크로로포름(CHCl3)으로 용출시켜 6g의 소분획물을 얻고 이를 다시 실리카겔 칼럼에 충진하여 핵산 : 에틸이세테이트를 3 : 1 및 8 : 5로 한 것으로 용출시켜 2g의 유파티린을 얻었다.As shown in Figure 1, 2 kg of Artemisia mongolica (70 g) extracted with 70% methanol three times was extracted from methanol extract (250 g) with nucleic acid and then fractionated with chloroform (CHCl 3 ). Column), eluted with chloroform (CHCl 3 ) to obtain 6 g of a small fraction, which was then charged into a silica gel column, followed by elution of 3: 1 and 8: 5 of nucleic acid: ethyl acetate to 2 g of oil. Got patrin.
이것을 메탄올로 재결정하여 여과하면 담황색의 침상결정을 가지며 융점이 232-233℃이고 분자량이 344인 유파티린을 얻었다.The crystals were recrystallized from methanol and filtered to obtain a euphorin having a pale yellow needle crystal and a melting point of 232-233 占 폚 and a molecular weight of 344.
그림 1. 유파티린 분리 과정도Figure 1. Eupatilin separation process
[실시예 2]Example 2
실시예 1에서 추출 분리한 유파티린의 위염 및 궤양에 대한 치료효과는 인위적으로 위염 및 궤양을 유발시킨 흰쥐를 대상으로 하였다.The therapeutic effect of the eutrophic acid extracted from Example 1 on gastritis and ulcers was induced in rats that artificially induced gastritis and ulcers.
위염 및 궤양 유발 방법은 염산·아스피린 유발위염과 아스피린 유발궤양모델을 이용하였다. 즉 전자의 방법은 24시간 절식시킨 흰쥐 체중 100g당 염산 15mM과 아스피린 20mg의 혼합 현탁액을 경구투여하고 1시간후에 부검관찰하는 방법(Guth등의 방법)이다.For gastritis and ulcer induction, hydrochloric acid, aspirin-induced gastritis and aspirin-induced ulcer model were used. That is, the former method is a method of orally administering a mixed suspension of 15 mM hydrochloric acid and 20 mg of aspirin per 100 g of rats fasted for 24 hours, and autopsy is observed one hour later (Guth et al.).
후자의 방법은 24시간 질식시킨 흰쥐를 에테르로 마취하고 개복하여 위의 유문부를 결찰하고 약물을 십이지장내 주입하고 복부를 봉합한 다음, 체중 100g당 아스피린 15mg에 해당하는 현탁액을 경구투여하고 7시간 후에 발생하는 위궤양의 크기 정도를 측정하는 방법(Okabe등의 방법)에 준하여 실시한 것이다.The latter method was anesthetized with ether for 24 hours, anesthetized with ether, ligated the stomach pylorus, intraduodenal injection of the drug, sutured the abdomen, and then orally administered a suspension equivalent to 15 mg of aspirin per 100 g of body weight. This was done according to the method of measuring the magnitude of gastric ulcers (Okabe et al.).
이와 같이 위염 및 궤양을 유발시킨 흰쥐에 살린, 유파티린, 시메티틴으로 처리한 결과를 표 1, 표 2에 나타내었다.Thus, the results of treatment with saline, eupatilin, and cimetin in rats causing gastritis and ulcer are shown in Table 1 and Table 2.
[표 1] 염산·아스피린 유발 위염에 대한 유파티린의 효과[Table 1] Effect of Eupatilin on Hydrochloric Acid and Aspirin-Induced Gastritis
[표 2] 아스피린 유발 궤양에 대한 유파티린의 효과Table 2.Effect of Eupatilin on Aspirin-induced Ulcers
대조군에 비한 유의성 차이(*P0.05**P0.01)Significance difference compared to control group (* P0.05 ** P0.01)
상기표 1,2에서 보듯이 유파티린을 염산·아스피린 유발 위염에 대해 동물 체중 1Kg당 28mg에서 약 78%의 위염 억제율을 나타내었고, 아스피린 유발궤양에서는 28mg의 같은 양에서 약 82%의 억제율을 나타내어 시메티딘보다 약 5배의 강한 효력을 나타내었다. 또한 유파티린의 급성독성에 있어서 LD50은 마우스에서 3,00mg/kg(경구투여)이상으로서 독성이 매우 약함을 알 수 있다.As shown in Tables 1 and 2, the upatirin-induced gastritis suppression rate was about 78% to 28% per kilogram of body weight for hydrochloric acid and aspirin-induced gastritis. It was about 5 times stronger than cimetidine. In addition, in the acute toxicity of upatirin LD 50 is more than 3,00mg / kg (oral administration) in the mouse is very toxic.
따라서 본 발명의 유라티린은 공지의 시메티딘보다 항위염 항궤양제로서 유효하며, 이의 추출원인 참쑥은 자원이 풍부하기 때문에 저가로 안정하게 생산할 수 있다.Therefore, the uratirin of the present invention is more effective as an anti- gastritis antiulcer agent than known cimetidine, and its extract source, mugwort, can be stably produced at low cost because of its rich resources.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019940000147A KR0127777B1 (en) | 1994-01-06 | 1994-01-06 | Anti gastritis and anti-ulcer drugs in upatiline |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019940000147A KR0127777B1 (en) | 1994-01-06 | 1994-01-06 | Anti gastritis and anti-ulcer drugs in upatiline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR950023405A KR950023405A (en) | 1995-08-18 |
| KR0127777B1 true KR0127777B1 (en) | 1998-04-01 |
Family
ID=19375323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019940000147A Ceased KR0127777B1 (en) | 1994-01-06 | 1994-01-06 | Anti gastritis and anti-ulcer drugs in upatiline |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR0127777B1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100414453B1 (en) * | 1996-07-12 | 2004-04-03 | 동아제약 주식회사 | Mugwort Extract for Inflammatory Growth Disease |
| KR100404443B1 (en) * | 1996-10-10 | 2004-04-14 | 동아제약 주식회사 | Pharmaceutical composition for treating gastritis and peptic ulcer |
| KR100967832B1 (en) * | 2009-09-24 | 2010-07-07 | 김진하 | Antibacterial composition comprising the extract of artemisia and the extract of nelumbo nucifera gaertner as an active ingredient |
| KR20160076511A (en) | 2016-06-21 | 2016-06-30 | 지엘팜텍 주식회사 | Artemisia extract |
| US11992434B2 (en) | 2015-03-31 | 2024-05-28 | Zoll Circulation, Inc. | Cold plate design in heat exchanger for intravascular temperature management catheter and/or heat exchange pad |
| US12305631B2 (en) | 2015-04-01 | 2025-05-20 | Zoll Circulation, Inc. | Heat exchange system for patient temperature control with easy loading high performance peristaltic pump |
| US12508155B2 (en) | 2014-02-14 | 2025-12-30 | Zoll Circulation, Inc. | Fluid cassette with polymeric membranes and integral inlet and outlet tubes for patient heat exchange system |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101000951B1 (en) * | 2004-07-03 | 2010-12-13 | 동아제약주식회사 | Leafy leaf extract from which blood coagulation inhibitor is removed, preparation method thereof, and pharmaceutical composition containing same as active ingredient |
| KR100739456B1 (en) * | 2005-07-14 | 2007-07-19 | 인하대학교 산학협력단 | Prevention and treatment of vaginitis containing sesame extract |
-
1994
- 1994-01-06 KR KR1019940000147A patent/KR0127777B1/en not_active Ceased
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100414453B1 (en) * | 1996-07-12 | 2004-04-03 | 동아제약 주식회사 | Mugwort Extract for Inflammatory Growth Disease |
| KR100404443B1 (en) * | 1996-10-10 | 2004-04-14 | 동아제약 주식회사 | Pharmaceutical composition for treating gastritis and peptic ulcer |
| KR100967832B1 (en) * | 2009-09-24 | 2010-07-07 | 김진하 | Antibacterial composition comprising the extract of artemisia and the extract of nelumbo nucifera gaertner as an active ingredient |
| US12508155B2 (en) | 2014-02-14 | 2025-12-30 | Zoll Circulation, Inc. | Fluid cassette with polymeric membranes and integral inlet and outlet tubes for patient heat exchange system |
| US11992434B2 (en) | 2015-03-31 | 2024-05-28 | Zoll Circulation, Inc. | Cold plate design in heat exchanger for intravascular temperature management catheter and/or heat exchange pad |
| US12305631B2 (en) | 2015-04-01 | 2025-05-20 | Zoll Circulation, Inc. | Heat exchange system for patient temperature control with easy loading high performance peristaltic pump |
| KR20160076511A (en) | 2016-06-21 | 2016-06-30 | 지엘팜텍 주식회사 | Artemisia extract |
Also Published As
| Publication number | Publication date |
|---|---|
| KR950023405A (en) | 1995-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0127777B1 (en) | Anti gastritis and anti-ulcer drugs in upatiline | |
| US4038416A (en) | Pharmaceutical composition and method of the use thereof | |
| US4871763A (en) | Method of treating liver diseases using pure silibinin | |
| EP2124930B1 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
| EP0192056B1 (en) | Process for the preparation of labdane derivatives, and their pharmaceutical use | |
| FI89369C (en) | Process for the preparation of pharmaceutically active 3-L-pyroglutamoyl-L-thiazolidine-4-carboxylic acid | |
| KR0178794B1 (en) | Oxidized-type glutathione alkyl ester | |
| EP0286643B1 (en) | Pharmaceutically active derivatives of glutamic and aspartic acids | |
| JPH01157962A (en) | Esterified azacyclohydroxy compound | |
| SU1151209A3 (en) | Method of obtaining alpha-tocopheryl esters of 5-substituted picoline acid | |
| JPS6362494B2 (en) | ||
| WO2002094302A1 (en) | Compositions comprising extract of ganoderma lucidum, oleamide and its structural analogue as an effective component for preventing or treating dementia | |
| JPH08231396A (en) | Anti-helicobacter pylori medicine | |
| SU1657062A3 (en) | Method for preparation of 2-thiazolidinone derivatives | |
| CA1139670A (en) | Process and composition for reducing blood pressure in animals | |
| EP1685134A1 (en) | Novel chelidonine derivatives, methods for the production thereof, and use thereof for producing pharmaceutical agents | |
| DK225986A (en) | PHARMACEUTICAL COMPOSITION OF THE TYPE OF PROMEDICATION AND METHOD OF PREPARING THE SAME | |
| DE2656852A1 (en) | 4-AMINO-QUINOLINE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND THE MEDICINAL PRODUCTS CONTAINING THEM | |
| JP2005523301A (en) | PHARMACEUTICAL COMPOSITION CONTAINING EXTRACT FROM BALLERIAPRIORITISINLIN AND METHOD FOR PREPARING THE SAME | |
| KR890000381B1 (en) | Method for preparing acylaminophenol derivative | |
| CA2032092A1 (en) | Antitumor agent | |
| JPH06211674A (en) | Anti-ulcer agent | |
| US4031186A (en) | Arylaminoalkylthioamides | |
| SU869267A1 (en) | N-[4-(3,3-dimethyltriazeno)phenylsulfonyl] isovalerylamide displaying anti-inflammatory activity | |
| US4835176A (en) | Glycookadaic acid, preparation thereof and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19940106 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19940126 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19940106 Comment text: Patent Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19970616 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19970806 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 19971024 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 19971024 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20001020 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20001221 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20020104 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20030204 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20040107 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20041228 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20060103 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20061218 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20080102 Start annual number: 12 End annual number: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20081231 Start annual number: 13 End annual number: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20100104 Start annual number: 14 End annual number: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20101229 Start annual number: 15 End annual number: 15 |
|
| J204 | Request for invalidation trial [patent] | ||
| PJ0204 | Invalidation trial for patent |
Patent event date: 20110729 Comment text: Request for Trial Patent event code: PJ02042R01D Patent event date: 19971024 Comment text: Registration of Establishment Patent event code: PJ02041E01I Appeal kind category: Invalidation Request date: 20110729 Decision date: 20121123 Appeal identifier: 2011100001807 |
|
| PR1001 | Payment of annual fee |
Payment date: 20111226 Start annual number: 16 End annual number: 16 |
|
| J301 | Trial decision |
Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20110729 Effective date: 20121123 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S05D Patent event date: 20121123 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Appeal kind category: Invalidation Request date: 20110729 Decision date: 20121123 Appeal identifier: 2011100001807 |
|
| J2X1 | Appeal (before the patent court) |
Free format text: INVALIDATION |
|
| PJ2001 | Appeal |
Patent event date: 20121123 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S05I Appeal kind category: Invalidation Decision date: 20130627 Appeal identifier: 2012200011269 Request date: 20121224 |
|
| PR1001 | Payment of annual fee |
Payment date: 20121226 Start annual number: 17 End annual number: 17 |
|
| J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20121224 Effective date: 20130627 |
|
| PJ1302 | Judgment (patent court) |
Patent event date: 20130717 Comment text: Written Judgment (Patent Court) Patent event code: PJ13021S01D Request date: 20121224 Decision date: 20130627 Appeal identifier: 2012200011269 Appeal kind category: Invalidation |
|
| J2X2 | Appeal (before the supreme court) |
Free format text: APPEAL BEFORE THE SUPREME COURT FOR INVALIDATION |
|
| PJ2002 | Appeal before the supreme court |
Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event date: 20121123 Patent event code: PJ20021S05I Request date: 20130725 Appeal identifier: 2013300001863 Appeal kind category: Invalidation Decision date: 20131011 |
|
| EXTG | Ip right invalidated | ||
| PC2102 | Extinguishment |
Termination category: Others Termination date: 20131104 |
|
| J303 | Written judgement (supreme court) |
Free format text: JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20130725 Effective date: 20131011 |
|
| PJ1303 | Judgment (supreme court) |
Comment text: Written Judgment (Supreme Court) Patent event date: 20131104 Patent event code: PJ13031S01D Decision date: 20131011 Appeal kind category: Invalidation Request date: 20130725 Appeal identifier: 2013300001863 |